Top Story

Ixazomib may provide more convenient, effective treatment for multiple myeloma

December 21, 2014

SAN FRANCISCO — Shaji K. Kumar, MD, professor of medicine at the Mayo Clinic in Rochester, Minn., discusses the experimental agent, ixazomib, which may provide patients with multiple myeloma with a more convenient treatment regimen.

Currently, the only available proteasome inhibitors are bortezomib (Velcade; Millennium) and carfilzomib (Kyprolis; Onyx) and they are can only be administered intravenously or through a subcutaneous injection.

Vosaroxin combination demonstrated improved survival in AML Meeting News CoverageVideo

Vosaroxin combination demonstrated improved survival in AML

December 20, 2014
SAN FRANCISCO — Farhad Ravandi, MD, professor of medicine in the department of leukemia at The University of Texas MD Anderson Cancer Center, discusses data from…

New next-generation sequencing test launched for thyroid nodules

December 20, 2014
Interpace Diagnostics, a molecular diagnostics subsidiary of PDI, Inc., has recently launched a new next-generation sequencing test designed to determine the difference…
In the Journals

ST2 levels predicted acute GVHD, mortality after double-unit cord blood transplantation

December 19, 2014
High levels of the biomarker suppressor of tumorigenicity 2 at 28 days post-cord blood transplantation independently predicted acute graft-versus-host disease, according…
In the Journals

Anticoagulant, antiplatelet medications carry rare dermatologic surgery hemorrhage risks

December 19, 2014
Dermatologists and dermatologic surgeons should be aware of the bleeding risks of anticoagulant and antiplatelet drugs used for cardiovascular diseases, according to…
More News Headlines »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
Vosaroxin combination demonstrated improved survival in AML

Vosaroxin combination demonstrated improved survival in AML

December 20, 2014
SAN FRANCISCO — Farhad Ravandi, MD, professor of medicine in the department of leukemia at The University of…
More »
CME
Hot melanoma

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
morganatic-roan